Sign In
Buy BIIB
$207.94
+1.66 (+0.80%)
At Close: Aug 07, 2026
FDA & EMA Accept Biogen's Filings for Higher Dose SMA Drug
07:32am, Friday, 24'th Jan 2025
BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.
FDA and EMA Accept Applications for Higher Dose Regimen of Nusinersen in SMA
07:30am, Thursday, 23'rd Jan 2025
Applications are based on data from the DEVOTE study, which demonstrate the potential for the investigational higher dose regimen of nusinersen to advance the treatment of SMA Applications are based o
The Genetic Toxicology Testing market is expected to rise due to rising genetic disease incidence, advancements in genetic toxicology testing technologies, increased R&D activities, strategic collabor
Billionaire Sells Palantir Stock and Buys This Stock That Could Soar 64% According to a Wall Street Expert
07:30am, Tuesday, 21'st Jan 2025
Billionaire investor Ken Griffin is the founder of Citadel Advisors, one of the world's most successful alternative investment firms.
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
09:20am, Wednesday, 15'th Jan 2025
Biogen Inc. (BIIB) J.P. Morgan 43rd Annual Healthcare Conference (Transcript)
Biogen CEO sees no burning need for more acquisitions
06:01pm, Tuesday, 14'th Jan 2025
Biogen expects revenue from new launches to exceed its current sales by 2028 and does not feel the need to chase additional business development deals, the company's CEO said.
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience of a subcutaneous injection with at-home administration option LEQEMBI is the only FDA-approved anti-
Biogen Offers to Buy Remaining Stake in Sage Therapeutics
04:01pm, Monday, 13'th Jan 2025
Biogen offers to buy the remaining stake in Sage Therapeutics for $7.22 per share. SAGE stock rises.
Sage Therapeutics shares surge on unsolicited takeover bid from Biogen
11:51am, Monday, 13'th Jan 2025
Sage Therapeutics (NASDAQ:SAGE) stock soared after the firm announced that it had received an unsolicited takeover bid from Biogen Inc (NASDAQ:BIIB, ETR:IDP). Biogen has proposed to acquire all of S
Sage takeout bid implies zero enterprise value, says Mizuho
11:31am, Monday, 13'th Jan 2025
Sage Therapeutics + Biogen -0.36 (-0.24%)
Biogen bid for Sage does not change narrative, says BMO Capital
09:39am, Monday, 13'th Jan 2025
Biogen -1.98 (-1.31%) Sage Therapeutics -0.29 (-4.96%)
Sage Therapeutics takeover bid undervalues Zurzuvae, says Truist
09:35am, Monday, 13'th Jan 2025
Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)
BofA moves to No Rating on Sage Therapeutics after Biogen bid
09:29am, Monday, 13'th Jan 2025
Sage Therapeutics -0.29 (-4.96%) Biogen -1.98 (-1.31%)
Sage Therapeutics Stock Rockets 35% Higher After Takeover Bid From Biogen
07:24am, Monday, 13'th Jan 2025
The biopharmaceutical company says its board of directors will now review and evaluate the offer from Biogen.
Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen
06:49pm, Friday, 10'th Jan 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) (“The Company”), today confirmed that Biogen Inc. (Nasdaq: BIIB) (“Biogen”) has submitted to the Company an unsolicite
